Earth Science Tech Reports 8% Revenue Growth via Vertical Integration
The company is leveraging a conglomerate model across telemedicine and pharmaceuticals to capture margins throughout the patient journey.
Earth Science Tech (OTC: ETST) has reported an 8% increase in revenue for fiscal 2026, attributing the growth to a strategic shift toward vertical integration. The company is consolidating its healthcare operations to control the entire value chain, from initial consultation to medication delivery.
According to company reports and financial data, the 8% revenue climb was accompanied by corresponding increases in both net income and gross profit. This growth is fueled by a vertically integrated ecosystem that includes subsidiaries Peak Curative, RxCompound, and Mister Meds. To further its reach, ETST launched a dedicated telehealth and pharmacy platform at myonlineconsultation.com, streamlining the process for patients to access care and prescriptions.
The Conglomerate Strategy
Earth Science Tech operates as a diversified holding company within the health and wellness sector. Rather than following a traditional healthcare provider model, ETST has adopted a conglomerate approach, acquiring and managing autonomous, revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate. A key component of this infrastructure is the MOCTeledoc platform, which serves as a B2B engine providing clinical staffing solutions and technology to other digital health firms.
Market Implications
By integrating telemedicine consultations with compounding pharmacies and fulfillment services, ETST effectively owns the entire patient journey. This structure reduces consumer friction and allows the company to capture profit margins at every stage of the process. In a crowded digital health market, this level of control over the supply chain positions the company to scale more efficiently than providers who rely on third-party pharmacies or staffing agencies.
Future Outlook
As ETST continues to expand its integrated ecosystem, the market will be watching for the scalability of the MOCTeledoc B2B platform and the adoption rates of the myonlineconsultation.com portal. The company's ability to maintain this growth trajectory will depend on how effectively it can synchronize its diverse holdings in real estate and retail with its core pharmaceutical and telehealth operations.